SCHEMBL390019

SCHEMBL390019

CC(C)OC(=O)N1CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
POLB P06746 1/20 0.45
HSD11B1 P28845 1/20 0.44
HTT P42858 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
TSHR P16473 2/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
GLA P06280 1/20 0.38
GPR119 Q8TDV5 2/20 0.38
GAA P10253 1/20 0.38
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
MMP1 P03956 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12282193 1.00 ALDH1A1 (0.45) ALDH1A1POLBHSD11B1HTTSMN1; SMN2
SCHEMBL12283406 1.00 ALDH1A1 (0.45) ALDH1A1POLBHSD11B1HTTSMN1; SMN2
SCHEMBL5412873 0.98 ALDH1A1 (0.42) ALDH1A1POLBHSD11B1HTTSMN1; SMN2
SCHEMBL2654623 0.93 TSHR (0.40) ALDH1A1POLBHSD11B1SMN1; SMN2TSHR
SCHEMBL10365765 0.84 ALDH1A1 (0.44) ALDH1A1POLBHSD11B1HTTSMN1; SMN2
SCHEMBL22978699 0.84 ALDH1A1 (0.44) ALDH1A1POLBHSD11B1HTTSMN1; SMN2
SCHEMBL16965092 0.84 ALDH1A1 (0.42) ALDH1A1POLBHSD11B1HTTSMN1; SMN2
SCHEMBL22978675 0.83 ALDH1A1 (0.42) ALDH1A1POLBHSD11B1HTTSMN1; SMN2
SCHEMBL29116529 0.83 ALDH1A1 (0.42) ALDH1A1POLBHSD11B1HTTSMN1; SMN2
SCHEMBL6886633 0.83 ALDH1A1 (0.42) ALDH1A1POLBHSD11B1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109415381-A Thiazolopyridine derivatives as GPR119 agonist 人类制药有限公司 2019-03-01 CN claimed
CN-109415359-A heterocyclic GPR119 agonist compounds 人类制药有限公司 2019-03-01 CN claimed
CN-105189498-B Geminally substituted cyanoethylpyrazolopyridinones as JANUS kinase inhibitors 默沙东公司 2017-06-27 CN claimed
CN-101801954-B Compounds and compositions as modulators of GPR119 activity IRM LLC 2013-10-09 CN claimed
CN-103328482-A New bicyclic compound for modulating G protein-coupled receptors HANMI PHARM IND CO LTD 2013-09-25 CN claimed
CN-102918027-A Modulators of the gpr119 receptor and the treatment of disorders related thereto ARENA PHARM INC 2013-02-06 CN claimed
CN-102803255-A Novel GPR 119 agonists CADILA HEALTHCARE LTD 2012-11-28 CN claimed
CN-101679258-A 4-piperidinylurea compounds as soluble epoxide hydrolase inhibitors ARETE THERAPEUTICS INC 2010-03-24 CN claimed
US-20070232559-A1 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2007-10-04 US claimed
WO-2024206514-A1 COUMARIN PHOTOBASE GENERATORS FOR POLYIMIDE FORMATION NITTO DENKO CORPORATION (JP) 2024-10-03 WO disclosed
CN-116249697-A Bicycloheptane pyrrolidine orexin receptor agonists 默沙东有限责任公司 2023-06-09 CN disclosed
WO-2023020519-A1 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-02-23 WO disclosed
WO-2022188729-A1 FUSED RING DERIVATIVES USEFUL AS KRAS G12D INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-09-15 WO disclosed
CN-114514023-A Methods of treating pancreatic cancer using RAD51 inhibitors 赛泰尔治疗公司 2022-05-17 CN disclosed
WO-2005007647-A1 TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2005-01-27 WO disclosed
CN-1265661-A N-acylamino acid amide compounds and intermediates for preparation thereof UBE INDUSTRIES (JP) 2000-09-06 CN disclosed
CN-1061595-A Be used as new heterocyclics of excited amino acid receptor antagonists and its production and use AKTIEBOTAGEL ASTRA (SE) 1992-06-03 CN disclosed
US-4234484-A FROM ALKOXYLATED CYCLIC AMIDES USING AS A CATALYST A QUATERNARY AMMONIUM OR ALKALI METAL SALT OF TETRAFLUOROBORIC OR HEXAFLUOROPHOSPHORIC ACID HOECHST AKTIENGESELLSCHAFT (DE) 1980-11-18 US disclosed
US-4149941-A ELECTROLYTIC ALKOXYLATION HOECHST AKTIENGESELLSCHAFT (DE) 1979-04-17 US disclosed
US-4118500-A Fungicidal alkoxy mono- and dialkoxy N-substituted cyclic amines HOECHST AKTIENGESELLSCHAFT (DE) 1978-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232559-A1 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF ADORA2A, ADORA3, ADORA1 ALDH1A1 635/4885POLB 2203/4885HSD11B1 2526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.